Zydus Life gets final USFDA nod for Norepinephrine Bitartrate Injection

Image
Capital Market
Last Updated : Jul 21 2022 | 8:50 AM IST

The drug maker said it received final approval from the US drug regulator to market Norepinephrine Bitartrate Injection USP,4 mg/4 mL (1 mg/mL) single-dose vial.

Norepinephrine Bitartrate is indicated for restoration of blood pressure in adult patients with acute hypotensive state.

The drug will be manufactured at the group's topical injectable manufacturing facility at Jarod in Gujarat (India).

Norepinephrine Bitartrate Injection USP, 1mg/1 mL had annual sales of $63.8 million in the United States according to IQVIA data (IQVIA MAT May 2022).

The group now has 317 approvals and has so far filed over 420* ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

Zydus Lifesciences reported 41.5% fall in consolidated net profit to Rs 397.4 crore despite a 5.3% increase in total income from operations to Rs 3,863.8 crore in Q4 FY22 over Q4 FY21.

The scrip rose 0.42% to settle at Rs 358.70 on Wednesday.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

SAVE 25%

More From This Section

First Published: Jul 21 2022 | 8:29 AM IST

Next Story